Quince Therapeutics/$QNCX
1D1W1MYTD1Y5YMAX
Capital at risk
About Quince Therapeutics
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
- Ticker
- $QNCX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 38
- Headquarters
- South San Francisco, United States
- Website
- quincetx.com
QNCX Metrics
BasicAdvanced
$30M
-
-$51.81
1.26
-
Price and volume
Market cap
$30M
Beta
1.26
52-week high
$35.41
52-week low
$15.10
Average daily volume
24K
Financial strength
Current ratio
14.519
Quick ratio
14.233
Profitability
EBITDA (TTM)
-60.647
Effective tax rate (TTM)
2.29%
Management effectiveness
Return on assets (TTM)
-31.51%
Return on equity (TTM)
-153.84%
Valuation
Price to book
-0.85
Price to tangible book (TTM)
-0.85
Price to free cash flow (TTM)
-1.12
Free cash flow yield (TTM)
-89.32%
Free cash flow per share (TTM)
-26.33
Growth
Earnings per share change (TTM)
-76.55%
3-year earnings per share growth (CAGR)
-32.84%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.